Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
PDSB 
PDS Biotechnology Corp (PDSB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: PDSB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -56.05% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 56.66M USD | Price to earnings Ratio - | 1Y Target Price 8.12 |
Price to earnings Ratio - | 1Y Target Price 8.12 | ||
Volume (30-day avg) 1021767 | Beta 1.67 | 52 Weeks Range 1.08 - 4.42 | Updated Date 03/31/2025 |
52 Weeks Range 1.08 - 4.42 | Updated Date 03/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.96 |
Earnings Date
Report Date 2025-03-25 | When Before Market | Estimate -0.275 | Actual -0.21 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -44.88% | Return on Equity (TTM) -174.49% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 32753766 | Price to Sales(TTM) - |
Enterprise Value 32753766 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.58 | Shares Outstanding 44589500 | Shares Floating 35993575 |
Shares Outstanding 44589500 | Shares Floating 35993575 | ||
Percent Insiders 3.11 | Percent Institutions 9.57 |
Analyst Ratings
Rating 4.8 | Target Price 11.5 | Buy 1 | Strong Buy 4 |
Buy 1 | Strong Buy 4 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
PDS Biotechnology Corp
Company Overview
History and Background
PDS Biotechnology Corp is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer and infectious diseases. Founded in 2006, it has progressed from initial research to clinical trials, focusing on its Versamuneu00ae and Infectimuneu2122 technology platforms.
Core Business Areas
- Versamuneu00ae Platform: This platform focuses on generating potent T-cell immunity against cancer targets. It delivers tumor-associated antigens to antigen-presenting cells to stimulate a strong immune response.
- Infectimuneu2122 Platform: This platform is designed to induce T-cell immunity against infectious diseases.
Leadership and Structure
The leadership team consists of experienced executives in the biotechnology and pharmaceutical industries, with expertise in drug development, clinical trials, and regulatory affairs. The organizational structure is typical of a clinical-stage biotech, with departments focused on R&D, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- PDS0101: A Versamuneu00ae-based immunotherapy being developed for HPV-associated cancers, including cervical, head and neck, and anal cancers. Currently in Phase 2 and Phase 3 clinical trials. Competitors include companies developing similar cancer immunotherapies, such as Merck (Keytruda) and Bristol Myers Squibb (Opdivo). Market share data is currently not available for a pre-market product. Revenue is $0.
- PDS0203: An Infectimuneu2122-based immunotherapy being developed for influenza. Currently in preclinical. Competitors include companies that produce seasonal flu vaccines, such as Sanofi, GSK, and CSL Seqirus. Market share data is currently not available for a pre-market product. Revenue is $0.
Market Dynamics
Industry Overview
The immunotherapy market is experiencing significant growth, driven by advancements in cancer research and the development of novel therapeutic approaches. Competition is high, with numerous companies developing new immunotherapies.
Positioning
PDS Biotechnology Corp is positioned as a developer of targeted immunotherapies, with its Versamuneu00ae platform offering a unique approach to generating potent T-cell responses. Its competitive advantage lies in its technology's ability to induce strong and durable immune responses.
Total Addressable Market (TAM)
The global cancer immunotherapy market is projected to reach hundreds of billions of dollars. PDS Biotech is positioned to capture a portion of this market by developing effective therapies for HPV-associated cancers and other indications.
Upturn SWOT Analysis
Strengths
- Novel Versamuneu00ae and Infectimuneu2122 technology platforms
- Promising preclinical and clinical data for PDS0101
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on clinical trial success
- Currently no products on the market generating revenue
Opportunities
- Expansion into new cancer indications
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results leading to regulatory approval
- Further development of the Infectimuneu2122 platform
Threats
- Clinical trial failures
- Competition from other immunotherapy developers
- Regulatory hurdles
- Market access challenges
Competitors and Market Share
Key Competitors
- MRK
- BMY
- GILD
Competitive Landscape
PDS Biotechnology Corp faces intense competition from established pharmaceutical companies and other biotechnology companies developing immunotherapies. Its advantage lies in its innovative technology platforms and targeted approach. Its disadvantage is limited resources compared to larger players.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: The company's growth has been primarily driven by the advancement of its clinical programs and preclinical pipeline. Historical data would reflect R&D expenditure growth not revenue growth.
Future Projections: Future growth is dependent on the successful completion of clinical trials and potential regulatory approvals for PDS0101 and other pipeline candidates. Analyst estimates vary widely depending on clinical trial outcomes.
Recent Initiatives: Recent initiatives include progressing PDS0101 through Phase 2 and Phase 3 clinical trials, expanding the pipeline with new programs, and strengthening partnerships with key opinion leaders.
Summary
PDS Biotechnology Corp is a clinical-stage biopharmaceutical company with promising Versamuneu00ae technology. Success hinges on clinical trial outcomes for PDS0101 and further pipeline development. It faces challenges related to funding, regulatory approvals, and competition from larger pharmaceutical companies. Positive results could lead to significant growth, while setbacks could negatively impact its valuation.
Similar Companies
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
GILD
Gilead Sciences Inc
GILD
Gilead Sciences Inc
MRK
Merck & Company Inc
MRK
Merck & Company Inc
VTVT
vTv Therapeutics Inc
VTVT
vTv Therapeutics Inc
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is based on publicly available information and should not be considered investment advice. The biotechnology industry is inherently risky, and past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About PDS Biotechnology Corp
Exchange NASDAQ | Headquaters Princeton, NJ, United States | ||
IPO Launch date 2015-10-01 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 25 | Website https://www.pdsbiotech.com |
Full time employees 25 | Website https://www.pdsbiotech.com | ||
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.